$FBIO News

Fortress Biotech Q1 EPS $2.82 Beats $(0.22) Estimate, Sales $16.038M Miss $16.338M Estimate

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech Q4 EPS $(0.30) Beats $(0.42) Estimate, Sales $16.079M Miss $21.018M Estimate

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

HC Wainwright & Co. Reiterates Buy on Fortress Biotech, Maintains $17 Price Target

Fortress Biotech Subsidiary Cyprium Therapeutics To Sell Rare Pediatric Disease Priority Review Voucher For $205M

Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States

Fortress Biotech Announces FDA Approves Its ZYCUBO To Treat Menkes Disease In Pediatric Patients

Fortress Biotech shares are trading higher after the company and its subsidiary, Cyprium Therapeutics, announced that the FDA has accepted the resubmission of the NDA for CUTX-101, intended to treat Menkes disease in pediatric patients.

Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

Fortress Biotech And Cyprium Therapeutics Announce FDA Acceptance Of Resubmission Of CUTX-101 NDA